Potential Roles of Long Noncoding RNAs as Therapeutic Targets in Organ Transplantation

Saeedeh Salehi1, Shima Afzali†1, Abbas Shahi1,2†, Ali Akbar Amirzargar1,2† and Yaser Mansoori2,3*†

1 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 2 Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran, 3 Department of Medical Genetics, Fasa University of Medical Sciences, Fasa, Iran

Organ transplantation is the most preferred treatment option for end-stage organ diseases; however, allograft rejection is the major hurdle in successful long-term transplant survival. In spite of developing better HLA matching and more effective immunosuppressive regimen, one-year graft survival has been increased by nearly 90% and the incidence of acute rejection by one-year post-transplantation has been decreased by 12.2% in the last decades, chronic allograft rejection has remained as one of the major obstacles to the long-lasting survival of the transplanted allograft. Therefore, seemingly preventing the allograft rejection and inducing immunological tolerance against transplanted allografts is one of the primary goals in transplantation research to enable long-lasting graft survival. Various mechanisms such as long noncoding RNAs (lncRNAs) have been proposed that induce immune tolerance by modulating the gene expression and regulating innate and adaptive immune responses during transplantation. Besides, because of involvement in regulating epigenetic, transcriptional, and post-translational mechanisms, lncRNAs could affect allograft status. Therefore, these molecules could be considered as the potential targets for prediction, prognosis, diagnosis, and treatment of graft rejection. It is suggested that the noninvasive predictive biomarkers hold promise to overcome the current limitations of conventional tissue biopsy in the diagnosis of rejection. Hence, this review aims to provide a comprehensive overview of lncRNAs and their function to facilitate diagnosis, prognosis, and prediction of the risk of graft rejection, and the suggestive therapeutic choices after transplantation.

Keywords: long noncoding RNA, transplantation, graft rejection, biomarker, solid organ

1 INTRODUCTION

1.1 Transplantation Perspective

Solid-organ transplantation is the most preferred treatment option for end-stage organ failure and could ameliorate life expectancy and quality, but allograft rejection is still the main barrier to long-term graft survival. Although widespread use of conventional immunosuppressive drug regimens and improvement in surgical techniques, HLA matching and cross-matching technologies have
significantly decreased the rate of allograft rejection, induction of the immunological tolerance and the long-lasting survival of transplanted organs have remained as the main challenges. Based on the 2019 annual data report of organ procurement and transplantation network (OPTN), the incidence of acute rejection by one year post-transplantation were 7% (1), 16% (2), 25.1% (3), 25.4% (4), 37.4% (5), and 12% (6) for Kidney, lung, heart, liver, intestine, and all categories of pancreas transplantation, respectively. Currently, routine monitoring of transplant recipients includes the measurement of biochemical parameters such as serum creatinine and protein excretion for renal transplant recipients, bilirubin and liver enzymes level consisting of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) for hepatic transplantation, and N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP), and cardiac troponin for heart transplant recipients (7, 8). But these markers are insensitive and non-specific and only detectable when the allograft dysfunction has occurred. Furthermore, accurate diagnosis of acute rejection requires allograft biopsy to confirm the underlying pathologies. Although the tissue biopsy is expensive, painful, and risky procedure and is limited by sampling error, inter-observer discrepancy in grading, and complications such as bleeding, infection, and allograft damage, currently it has been considered as a gold standard technique for investigating the graft status (9). Therefore, it is needed to identify a reliable and noninvasive methods that could replace biopsy or decrease the dependency on biopsy reporting. Hopefully, biomarkers in biofluids can be used to monitor the recipient’s immune response to the allograft in the near future. Noncoding RNAs (ncRNAs) are attracting widespread interest due to their ability in affecting the biological pathways which play important roles in health and disease. Besides, their stability in tissue and biofluids potentiates them as the appropriate candidates for biomarker discovery.

A growing body of evidence suggests that long non-coding RNAs (lncRNAs) have been participated in developmental, biological, and pathological processes through affecting various molecular pathways, such as transcription, post-transcription, and translation levels. In the rejection processes, the pathologic process could be detected at molecular level before occurrence of histological or clinical manifestations. Several investigations were carried out for profiling of lncRNAs in serum, plasma and urine samples of transplant rejected patients to find potential biomarkers for prognosis, diagnosis, and treatment of graft rejection (10–16).

To the best of our knowledge, no secondary study has assessed the role of IncRNAs in organ transplantation. Therefore, we aimed to conduct a comprehensive literature search and to summarize important results that coming from the original research which have evaluated the lncRNAs and their performance as predictive and/or diagnostic biomarkers for organ transplantation.

### 1.2 Noncoding RNAs

ENCODER (Encyclopedia of DNA Element) project has demonstrated that about 80% of the human genome is actively transcribed to at least one RNA, while only a small fraction (less than 3%) of them translate to the protein, and the remaining are non-protein-coding genes which transcribed but do not translate to the protein, consist of non-coding RNAs (ncRNAs) (17). ncRNA’s functions generally include regulation of gene expression at the transcriptional and post-transcriptional level. The ncRNAs are categorized into housekeeping and regulatory RNAs. Transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs) are two important examples of housekeeping ncRNAs which involved in protein synthesis. ncRNAs with regulatory function are mainly divided into three groups; (I) Small non-coding RNAs (sncRNAs; up to 50 nucleotides) such as small interfering RNA (siRNA), microRNA (miRNA) and piwi-interacting RNA (piRNA), (II) mid-size non-coding RNAs (mncRNAs; 50 to 400 nucleotides) include small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNA), small conditional RNA (sRNA), and short hairpin RNA (shRNA), and (III) long non-coding RNAs (lncRNAs; more than 400 nucleotides) (18–20). Schematic representation of ncRNAs has been depicted in Figure 1.

#### 1.2.1 History, Characteristics and Classification of IncRNAs

It has been revealed that the human genome is highly dynamic, and just 2.2% of the DNA sequence is conserved. Interestingly, more than 80% of IncRNAs are among the least conserved genes. The IncRNA H19 is the first non-coding gene discovered in 1989; however, it was classified as mRNA at that time.

There are various mechanisms that IncRNAs seemed to arise from, including alterations in protein-coding genes, such as losing the protein-coding potential, retrotransposition of a noncoding gene, chromosomal rearrangement, duplicating the already existing IncRNA sequences, as well as the transposable element which can make IncRNA by polyadenylation, splicing, RNA editing. Although the de novo origin of IncRNAs is difficult to prove; there are a few examples for it, such as Polidi that is a testis-specific IncRNA (21, 22).

IncRNAs are described as non-coding transcripts that are at least 200 nucleotides in length and could be find in nucleus, cytoplasm, and other compartments. These molecules are functional RNA elements that are normally expressed at low levels in a tissue-specific and time-limited mode, with half-lives varying from < 2h to > 16h and a median half-life of 3.5h. Although these molecules are poorly conserved among various species, their particular secondary structures, localization, and mechanisms of action appear to be highly conserved (23–25).

IncRNAs can be classified into five groups based on their location and proximity to protein-coding sequence, comprising of long intergenic noncoding RNAs (lincRNAs), sense or exonic, intronic, natural antisense transcript (NATs), and bidirectional or divergent IncRNAs (26, 27), or classified to four archetypes based on mechanism of action, including signal, decoy, guide, and scaffold (23, 28), or categorized to three groups based on their length, small IncRNA with 200 to 950 nucleotides, medium IncRNA with 950 to 4800 nucleotide, and large IncRNA with more than 4800 nucleotides (Figure 1). Small (58%) and medium (78%) IncRNAs are major IncRNA in the human and mouse, respectively (29). In humans, there are from 17948
IncRNAs predicted by GENCODE (30) to 96411 predicted by NONCODE (31). These differences between these two databases highlight either the massive number of IncRNA genes in the human genome and the growing need for ongoing IncRNAs research to discover these inter-databases discrepancies.

1.2.2 Biogenesis and Mechanism of Action of IncRNAs

IncRNAs are typical RNA molecules transcribed from exonic, intergenic, or distal eukaryotic genome regions by the RNA polymerase II, III enzymes or mitochondrial RNA polymerase IV.
enzyme. These molecules are processed to the mature RNA, similar to the protein-coding mRNAs. The immature RNA transcripts often undergo several processing steps for reaching the mature forms during and after transcription, such as 3′-polyadenylation, 5′-capping, splicing, and chemical base modification (24, 32).

LncRNAs can play several roles in the biological processes such as proliferation (PCNA-AS1), migration (H19), epigenetic regulation (HOTAIR), cell cycle (MALAT), cell death (MEG3), invasion (LncRNA-ATB), angiogenesis (ANRIL), autophagy (H19), apoptosis (PTENP1) and metastasis (HULC); as well as are found to be associated with several diseases such as rheumatoid arthritis, atherosclerotic coronary artery disease, diabetes, neurodegenerative disorders, and many types of cancers (32–35). As mentioned in previous section, lncRNAs, according to their mechanism of action, could classify into guide, decoy, scaffold, or signal and can modulate gene expression at the transcriptional level. As a guide, lncRNAs might activate or repress gene expression via relocalization of regulatory factors. Decoy lncRNAs act as an endogenous sponge for other molecules such as microRNAs and alter the bioavailability of the molecule, changing cellular function. Scaffold lncRNAs participate in the formation of ribonucleoprotein complexes. As a signal, lncRNAs could regulate gene expression (36, 37). The following are some examples of the mechanisms of action of lncRNAs.

(I) Regulating histone modifications; Important histone-modifying complexes that interact with lncRNAs include two repressive complexes: PRC1 and PRC2. X-inactive specific transcript (XIST) is a highly expressed lncRNA in females that silences gene expression by recruiting PRC2. Moreover, HOX transcript antisense RNA (HOTAIR), another lncRNA, can repress a locus named HoxD by interacting with PRC2; it can also interact with a histone demethylase and lead to developing repressive effect on chromatin by removing a histone mark. (II) Modulating DNA methylation; Tcf21 antisense RNA reducing DNA methylation (TARID) is a lncRNA involved in the mechanisms of DNA methylation. (III) Regulating chromatin remodeling; some lncRNAs play a role in controlling chromatin remodeling complexes which can change nucleosome spacing, such as embryonic ventral forebrain-1 (evf2) and myosin heavy chain associated RNA transcripts (MHRT) (38). (IV) Interacting with transcription factors, some lncRNAs take part in signal transduction by regulating initiation, elongation, and termination of transcription factor’s actions (32). The lncRNA named rhabdomyosarcoma associated transcript (RMST) mediates the binding of the SRY-Box Transcription Factor 2 (SOX2) transcription factor to its binding sites and play a role in neuronal differentiation. (V) Looping enhancers and regulating genome organization; for instance, prostate cancer-associated noncoding RNA 1 (PRNCR1) and prostate-specific transcript (PGGEM1) are two lncRNAs that increase the enhancer-promoter looping in cancer cells (38). (VI) Regulating post-transcriptional events; includes post-transcriptional modifications such as editing, splicing, and mRNA localization (32).

For example, Pnky is a neural-specific lncRNA that modulates the splicing patterns by binding to a splicing factor. (VII) Affecting development and differentiation, it has been indicated that female mice lacking XIST died during the first half of gestation (38). Another example of lncRNAs that affect development process are hematopoietic stem cell-specific lncRNAs (LncHSC). Likely LncHSC 1 and 2 participate in self-renewal, and myeloid differentiation, LncHSC6 involve in hematopoietic stem cell (HSC) differentiation, and LncHSC4 plays a role in erythroid lineage development and differentiation of blood cells. (VIII) Acting as a tumor suppressor; LncRNA growth arrest-specific 5 (Gas5) targets cancer-promoting miRNAs such as miR21 and plays a role as a tumor suppressor in T and B cell leukemia (32).

### 2 LncRNAs and Transplantation

The functions of lncRNAs in transplantation have attracted wide attentions. A growing body of literatures have investigated about the functions of several lncRNA categories in cell or organ transplantation. As the studies utilized mice/rat models or human samples, different aspects of lncRNAs activity have been assessed. Therefore, according to the design of studies, we categorized them into two categories: studies that have mainly evaluated mice/rat model of transplantation (animal studies; Table 1), and those which have used human samples (Table 2 and Figure 2).

#### 2.1 Animal Studies

##### 2.1.1 Heart

Some animal studies indicated that lncRNAs might be related to acute rejection episodes after cardiac transplantation. Gu et al. showed that two lncRNAs, called MouseLincrena1055 and A930015D03Rik, which were obtained in the plasma, were upregulated in mice with acute heart allograft rejection (11). LncRNAs have been linked to allograft survival via the functional modulation of dendritic cells (DCs) and immune tolerance induction. The evidence from previous study suggests that silencing some of the lncRNAs, such as nuclear enriched abundant transcript 1 (NEAT1), can induce tolerogenic phenotype in DCs (tol-DCs) by reducing the expression of the costimulatory molecules such as, CD80, CD86, and MHC-II through the interaction with miR-3076-3p (39). Adoptive transfer of the knocked down DCs prolonged allograft survival and has induced immune tolerance in heart transplanted mice by creating a regulatory state, including increasing the regulatory T (Treg) cells and anti-inflammatory cytokines IL-10 and TGF-β, decreasing infiltration of inflammatory cells and cytokines, and inhibiting T cell proliferation in a cardiac transplantation model (39, 64). Another lncRNA involved in the functional modulation of murine DCs is metastasis-associated lung adenocarcinoma transcript 1 (MALAT1). Wu et al. depicted that the adoptive transfusion of MALAT1-overexpressing DCs to cardiac transplanted mice can induce immune tolerance by increasing Treg cells infiltration to the cardiac allograft and enhancing
### TABLE 1: LncRNAs in the context of animal models of transplantation.

| Name of lncRNA | Chr | Sample type | Animal Study design | Potential finding | Ref. |
|----------------|-----|-------------|---------------------|-------------------|-----|
| **Heart TX**  |     |             |                     |                   |     |
| Mouselincrna1055 | – | Plasma | Mice | Case-control | † in transplant acute rejection process. |
| A930015D03Rik | 17 | Intergenic | PBLs | Biopsy | ↓ IFN-γ and TNF-α expression. |
|                 |     |             | Mice | Case-control | ↓ IL-12P40 and T-bet expression in CD4+ T cells. |
|                 |     |             | Mice | Case-control | ↓ in both plasma and PBLs of the allogeneic group compared to syngeneic group. |
| **Liver TX**   |     |             |                     |                   |     |
| LOC102553657   |     | Serum | Rat | 4 groups: Sham | ↑ 7.86-fold in BDDLT compared to control group. |
|                 |     | Tissue | Rat | BD | ↓ Trans regulation of HMOX1 via the HNF-3β transcription factor. |
| AABR06818038.2 |     |             | Rat | BDDLT | † in BDDLT compared to control group. |
| AABR06818038.1 |     |             | Rat | Control group | Negatively correlated with HMOX1, ATF3, TRIB3, and ANGPLT4. |
| LOC100911923   |     |             | Rat | BDDLT | ↓ in BDDLT compared to control group. |
| LOC103692721   |     |             | Rat | BDDLT | Positively correlated with cell apoptosis genes |
| **Lung TX**    |     |             |                     |                   |     |
| XIST | X | Intergenic | Tissue | Rat | XIST silencing → ↑ miR-21 → ↓ IL-12A → ↑ PMN apoptosis — inhibiting NET formation. |
| MALAT-1 | 11 | Tissue | Rat | Serum | MALAT-1 silencing → ↓ IL-8, MPO, and ROS — ↓ Neutrophile in filtration and activation — Improvement inflammatory injury in lung TX ischemia reperfusion. |
| – | – | Tissue | Mice | 8 Syngeneic TX | In the allogeneic model compared to the syngeneic control group: |
|                 |     |             | Mice | 8 Allogeneic TX | 249 lncRNAs upregulated |
| **Kidney TX** |     |             |                     |                   |     |
| PRINS | – | Blood | Rat | 6 iso-control | ↑ Expression of CXCL3 → ↑ PRINS expression — Leading to AKI which is exacerbated graft rejection. |
| MEG-3 | 12 | Intergenic | Tissue | Mice | siMEG-3 delivery to mice → MEG-3 knock-down — tmir-181b-5p — ↓ TNF-α — ↓ Tubular damage — Protection against renal injury post-TX — ↓ Serum creatinine. |
| **Stem cell TX** |     |             |                     |                   |     |
| ENSRNOT00000052577 | – | Intronic | Tissue | Rat | Up-regulated after A2B5+ iPSC TX — neurological function recovery |
| – | – | Tissue | Mice | Sham group | 1911 downregulated and 2918 upregulated lncRNAs in hepatocytes after HSCT. |

(Continued)
TABLE 1 | Continued

| Name of IncRNA | Chr | Sample type | Animal | Study design | Potential finding | Ref. |
|---------------|----|-------------|--------|--------------|------------------|-----|
| Corneal TX    | –  | –           | Corneal tissue | Rat | Control group | 285 IncRNAs had differential expression in normal group and autograft group: (50) |
|               |    |             | Corneal | Control group | 239 were upregulated and 46 were downregulated. |
|               |    |             | Corneal | 85 IncRNAs had differential expression in normal group and autograft group: |
|               |    |             | Corneal | 644 were upregulated and 241 were downregulated. |

TX, transplantation; IncRNA, long non-coding RNA; Chr., chromosome; PBL, peripheral blood lymphocytes; GIL, graft-infiltrating lymphocyte; NEAT1, Nuclear Enriched Abundant Transcript 1; DC, dendritic cell; MALAT1, metastasis associated lung adenocarcinoma transcript 1; BD, brain dead; BDALT, brain dead donor liver transplantation; HMOX1, Heme Oxgenase 1; HNF-3B, hepatocyte nuclear factor 3 beta; TRIB3, Tribbles homolog 3; ATF3, Activating transcription factor 3; ANGPTL4, Angiopoietin Like 4; IGF-6, Immunoglobulin heavy chain 6; TUG-1, Taurine up regulated 1; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HSCT, hematopoietic stem cell transplantation; TBI, traumatic brain injury; XIST, X-inactive specific transcript; PMN, polymorphonuclear; NET, neutrophil extracellular trap; PG2, primary graft dysfunction; MPO, myeloperoxidase; RDS, reactive oxygen species; BUN, blood urine nitrogen; MEG-3, maternally expressed gene 3.

splenic Tregs. Moreover, the transfer of MALAT1-overexpressing DCs elevated serum level of IL-10 and decreased IL-6 and IL-12 levels in the heart transplanted mice.

Ectopic MALAT1 upregulated dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN) expression level through functioning as a miR155 sponge in the cytoplasm of DCs (40).

2.1.2 Liver

During liver transplantation, cold-mediated hepatic damage is the main problem affecting liver graft survival rate. A high-throughput sequencing-based study has shown cold storage down-regulated taurine upregulated gene 1 (TUG1) expression, whereas TUG1 overexpression attenuates cold-mediated apoptosis via inhibiting intrinsic pathway of apoptosis and endoplasmic reticulum stress pathway in hepatocytes and hepatic sinusoidal endothelial cells (HSECs). Moreover, TUG1 overexpression in mice led to massive reduction of serum levels of hepatic enzymes, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) after transplantation. Therefore, overexpression of TUG1 appears to confer hepatic tissue protection and ameliorates hepatocyte functions following hepatic injury in a murine liver transplant model (42). Similar to TUG1, AABR06081886.1 upregulation has been negatively correlated with apoptosis-related key genes such as Heme Oxygenase 1 (HMOX1), tribbles pseudo kinase 3 (TRIB3), angiopoietin like 4 (ANGPTL4), and activating transcription factor 3 (ATF3) in brain dead donor liver transplant under the effect of Myc/Max transcription factor in mice with OB. Additionally, the expression of 9530082P21Rik and 2310001H17Rik IncRNAs were modulated via FOXO1 TF. Myc/Max and FOXO1 TFs might play pivotal roles in the development of OB in the murine models following lung transplantation by regulating downstream IncRNAs, mRNAs, and miRNAs (45). MALAT1 Silencing has also been demonstrated to improve the IRI in a rat model of lung transplantation by blocking neutrophils infiltration and activation through histone acetyltransferase p300-mediated downregulation of IL-8 (44). Furthermore, another recent study revealed that shRNA-mediated knockdown of XIST potentiated the apoptosis of polymorphonuclear neutrophils (PMNs) and thus prevented the formation of the neutrophil extracellular trap (NET) via upregulation of miR-21 and downregulation of IL-12A in a rat model of lung transplantation. Therefore, miR-21 overexpression ameliorates PGD after lung transplantation through downregulation of inflammatory mediators such as IL-6, IL-8, CCL-2, and CXCL-10 (43).

2.1.4 Kidney

Acute kidney injury (AKI) induced by prolonged cold ischemia could lead to acute rejection by enhancing the recruitment of various immune cells, like T cells. Interaction of CXCR-3 and its ligand, CXCL-10, has been depicted to be involved in the T cell immigration to the allograft in a rat model of renal transplantation (65). It has been shown that CXCL-10 can upregulate the expression of chemokine-related IncRNA called psoriasis susceptibility-related RNA gene induced by stress (PRINS) in the renal allografts subjected to cold ischemia in a rat model of kidney transplantation (46). Another IncRNA that was found to be upregulated after hypoxia treatment is maternally expressed gene 3 (MEG-3). Pang et al. suggested that MEG-3 as a competing endogenous RNA (ceRNA) for miR-181b leads to upregulation of tumor necrosis factor-alpha (TNF-α) in hypoxia-mediated renal damage in the mice model of transplantation. MEG3 inhibition via siMEG-3 delivery promoted and reduced miR-181b-5p levels and TNF-α expression, respectively. Consequently, these changes protect kidney allografts from tubular damage (47). These results
| Name of IncRNA | Chr* | LncRNA class* | Sample size | Sample type | Study design | Potential finding | Ref. |
|----------------|------|---------------|-------------|-------------|--------------|-------------------|------|
| Kidney TX RP11-354P17.15-001 (L328) | 9 | Intergenic | 62 aTCMR 31 SGF 10 anti-rejection therapy | Urine Case-control | ↑ in aTCMR patients. Normalized with anti-rejection therapies. Associated with higher decline in GFR 1-year post-TX. IL-6 treatment of tubular epithelial cells → ↑ L327 and L328 in cell culture supernatant. | (51) |
| RP11-395P13.3-001 (L327) | 5 | Intergenic | 5 | Urine Prospective cohort (Two-year follow-up) | ↑ in acute cellular rejection patients. | (10) |
| AF264622 | 2 | Intron | 75 pediatric (38 AR, 37 SGF) from GSE14346 | Blood Patient cohort | ↑ in acute rejection vs. stable patients in both pediatric and adult groups. | (38) |
| AB209021 | 3 | Exon | 75 Adult (51 AR, 19 SGF) from GSE15296 | Blood Prospective cohort (Two-year follow-up) | ↑ in acute rejection vs. stable patients in both pediatric and adult groups. | (51) |
| IncRNA-ATB | 14 | Exon | 72 aTCMR 36 SGF | Biopsy Case-control | ↑ in aTCMR patients. Inversely correlated with the renal tissue expression of miR-200c of aTCMR patients. lncRNA-ATB over-expression → CsA-mediated apoptosis of kidney cells. | (12) |
| ENST00000628900 RP11-309P22.1 | – | – | 5 Rejection 5 SGF 5 HC | Biopsy Case-control | ↑ in rejection cases compared to SGF and HC subjects. | (11) |
| OIP5-AS1 | 15 | Intergenic | 22 AMR | Blood Case-control | ↑ FAS-AS1 expression level in rejection group (AMR & TCMR) in males but not females. Expression levels of other lncRNAs were not differ between two groups. | (52) |
| FAS-AS1 | 10 | Antisense | 7 TCMR 32 SGF | Blood Case-control | ↑ MIR155HG expression ↑ graft rejection related pathways like GVHD, TCR and BCR signaling pathways. ↑ Four lncRNAs expression level → ↑ probability of TCMR (ORs > 1). | (53) |
| TUG1 | 22 | Intergenic | 32 SGF | Blood Case-control | ↑ MIR155HG associate with AR and the graft loss risk. | (53) |
| NEAT1 | 11 | Intergenic | 32 SGF | Blood Case-control | ↑ MIR155HG associate with AR and the graft loss risk. | (53) |
| PANDAR | 6 | Intergenic | 32 SGF | Blood Case-control | ↑ MIR155HG associate with AR and the graft loss risk. | (53) |
| ITGB2-AS1 | 21 | Antisense | 1105 samples from: GSE36059 GSE48581 | Biopsy In silico | Two lncRNAs associate with the graft loss risk. | (14) |
| CARD8-AS1 | 19 | Antisense | 1105 samples from: GSE36059 GSE48581 | Biopsy In silico | Two lncRNAs associate with the graft loss risk. | (14) |
| MR155HG | 21 | Intergenic | GSE36059 | Blood Case-control | ↑ MIR155HG associate with AR and the graft loss risk. | (53) |
| MIR3142HG | 5 | – | GSE48581 | Blood Case-control | ↑ MIR155HG associate with AR and the graft loss risk. | (53) |
| RPS5-117110.5 | 17 | Intergenic | GSE21374 | Blood Case-control | ↑ MIR155HG associate with AR and the graft loss risk. | (53) |
| RP11-1399P15.1 | 2 | Intergenic | GSE50058 | Blood Case-control | ↑ MIR155HG associate with AR and the graft loss risk. | (53) |
| IncRNA-ATB RP11-522B15.3 (AC093673.5) | 15 | Intergenic | 407 samples from: GSE21374 GSE25902 | Biopsy In silico | Considerably associated with the progressive chronic histological damage and graft failure an important role in prediction of graft fibrosis and progressive fibrosis at one year after TX. | (16) |
| ATP1A1-AS1 | 1 | Antisense | GSE34437, GSE75693, GSE50058, GSE76882, and GSE21374 | Biopsy In silico | The 4-lncRNA risk score model had a good sensitivity and specificity for AR of kidney allograft and prediction of the graft loss risk. The expression of these lncRNAs correlated with γT cells and eosinophils. | (53) |
| CTD-3080P12.3 | 5 | Intergenic | 129 PBMC | Biopsy In silico | The 4-lncRNA risk score model had a good sensitivity and specificity for AR of kidney allograft and prediction of the graft loss risk. The expression of these lncRNAs correlated with γT cells and eosinophils. | (53) |
| EMX2OS | 10 | Antisense | 129 PBMC | Biopsy In silico | The 4-lncRNA risk score model had a good sensitivity and specificity for AR of kidney allograft and prediction of the graft loss risk. The expression of these lncRNAs correlated with γT cells and eosinophils. | (53) |
| LINCO0645 | 14 | Intergenic | 129 PBMC | Biopsy In silico | The 4-lncRNA risk score model had a good sensitivity and specificity for AR of kidney allograft and prediction of the graft loss risk. The expression of these lncRNAs correlated with γT cells and eosinophils. | (53) |
| MGAT3-AS1 | 22 | Antisense | 129 PBMC | Cohort | ↑ in patients with plasma Tac levels< 15µg/mL compared to those have Tac levels≥15µg/mL in first postoperative day. ↑ by 76% during the one-week post-TX. ↑ in patients with DGF in comparison to patients with IGF post-TX. | (54) |
| MGAT3-AS1 | 22 | Antisense | 163 PBMC | Cohort | ↑ in patients with plasma Tac levels< 15µg/mL compared to those have Tac levels≥15µg/mL in first postoperative day. ↑ by 76% during the one-week post-TX. ↑ in patients with DGF in comparison to patients with IGF post-TX. | (54) |
| AC007114.2 | 17 | Antisense | 32 samples from: GSE66884 | PBMC In silico | There were 1063 differentially expressed lncRNAs and 3563 differentially expressed mRNAs. 466 lncRNA-mRNA pairs with cis-regulation. 5692 lncRNA-mRNA pairs with trans-regulation. These seven lncRNAs targeted ZBTB25 mRNA. | (56) |
| AL122035.2 | 14 | Antisense | GSE66884 | PBMC In silico | There were 1063 differentially expressed lncRNAs and 3563 differentially expressed mRNAs. 466 lncRNA-mRNA pairs with cis-regulation. 5692 lncRNA-mRNA pairs with trans-regulation. These seven lncRNAs targeted ZBTB25 mRNA. | (56) |
| AL591848.3 | 1 | Intergenic | GSE66884 | PBMC In silico | There were 1063 differentially expressed lncRNAs and 3563 differentially expressed mRNAs. 466 lncRNA-mRNA pairs with cis-regulation. 5692 lncRNA-mRNA pairs with trans-regulation. These seven lncRNAs targeted ZBTB25 mRNA. | (56) |
| IQCH-AS1 | 15 | Antisense | GSE66884 | PBMC In silico | There were 1063 differentially expressed lncRNAs and 3563 differentially expressed mRNAs. 466 lncRNA-mRNA pairs with cis-regulation. 5692 lncRNA-mRNA pairs with trans-regulation. These seven lncRNAs targeted ZBTB25 mRNA. | (56) |
| KLF3-AS1 | 4 | Antisense | GSE66884 | PBMC In silico | There were 1063 differentially expressed lncRNAs and 3563 differentially expressed mRNAs. 466 lncRNA-mRNA pairs with cis-regulation. 5692 lncRNA-mRNA pairs with trans-regulation. These seven lncRNAs targeted ZBTB25 mRNA. | (56) |
| PVT1 | 8 | Intergenic | GSE66884 | PBMC In silico | There were 1063 differentially expressed lncRNAs and 3563 differentially expressed mRNAs. 466 lncRNA-mRNA pairs with cis-regulation. 5692 lncRNA-mRNA pairs with trans-regulation. These seven lncRNAs targeted ZBTB25 mRNA. | (56) |
| PVT1 SLC25A25-AS1 | 9 | Antisense | GSE66884 | PBMC In silico | There were 1063 differentially expressed lncRNAs and 3563 differentially expressed mRNAs. 466 lncRNA-mRNA pairs with cis-regulation. 5692 lncRNA-mRNA pairs with trans-regulation. These seven lncRNAs targeted ZBTB25 mRNA. | (56) |
| Name of lncRNA | Chr* | LncRNA class* | Sample size | Sample type | Study design | Potential finding | Ref. |
|----------------|------|---------------|-------------|-------------|--------------|------------------|-----|
| TMEM161B-AS1   | 5    | Antisense     | 18 mRNAs such as ANGEL1, ARSK, CARF, CATSPER2, CD96, DIXF, ELP2, HLCS were target of this lncRNA in the first week post-TX compared to pre-TX. | Biopsy | Case-control | 5339 lncRNAs have differential expression between AR and NC group: 3148 lncRNAs down-regulated. 2191 lncRNAs up-regulated. 18 lncRNAs have highest total score. | (57) |
| AF113674       | 19   | Intronic      | 3 AR        | Biopsy | In silico | Located in TSS of C3 complement—possibly related to the innate immune response activation against allograft. | (58) |
| Uc010ftb       | 6    | ↑ in AR | circase 10 expression (negatively regulation circase 10) | Biopsy | Case-control | 32 lncRNAs were correlated with AR pathophysiology. | (59) |
| Uc001fty       | 1    | Intronic      | ↓ in AR | Located on intronic region of CRP | 2191 lncRNAs up-regulated. 18 lncRNAs have highest total score. | (57) |
| Uc003wbj       | –    | –            | ↑ in AR | Corresponding to the TCR-β mRNA. | 32 lncRNAs were correlated with AR pathophysiology. | (57) |
| AK129917       | 2    | –            | ↑ in AR | Located in TSS of Hsp-90 | 32 lncRNAs were correlated with AR pathophysiology. | (57) |
| NR_002196      | –    | 25 HC        | ↑ in AR | Located on intronic region of CRP | 2191 lncRNAs up-regulated. 18 lncRNAs have highest total score. | (57) |
| MIRLET7BH3    | 22   | Intergenic   | 25 non-rejection | Cross section | ↑ in AR in the graft rejected group. | (57) |
| TUG-1 (NR_002323) | 22   | Intergenic   | 25 non-rejection | Cross section | ↑ in AR in the graft rejected group. | (57) |
| NR_125893      | 4    | Intergenic   | ↑ in AR | Located on intronic region of CRP | 2191 lncRNAs up-regulated. 18 lncRNAs have highest total score. | (57) |
| LNC-EPHA6      | 3    | Antisense    | 15 AR       | Biopsy | Case-control | 32 lncRNAs were correlated with AR pathophysiology. | (57) |
| LNC-RPS24      | 10   | Intergenic   | 15 AR       | Biopsy | Case-control | 32 lncRNAs were correlated with AR pathophysiology. | (57) |
| LIPCAR         | mt   | Intergenic   | 15 AR       | Biopsy | Case-control | 32 lncRNAs were correlated with AR pathophysiology. | (57) |
| XIST           | X    | Intergenic   | 15 AR       | Biopsy | Case-control | 32 lncRNAs were correlated with AR pathophysiology. | (57) |
| ANRIL          | 9    | Antisense    | 505         | Blood | Cohort | 2191 lncRNAs up-regulated. 18 lncRNAs have highest total score. | (57) |
| LIPCAR         | mt   | Intergenic   | 35 SPKT     | Plasma | Case-control | 32 lncRNAs were correlated with AR pathophysiology. | (57) |
| LNC-RPS24      | 10   | Intergenic   | 13RTX       | Plasma | Case-control | 32 lncRNAs were correlated with AR pathophysiology. | (57) |
| MALAT1         | 11   | Intergenic   | 15HC        | Plasma | Case-control | 32 lncRNAs were correlated with AR pathophysiology. | (57) |
| LNC-EPHA6      | 3    | Antisense    | 32 SGF      | Plasma | Case-control | 32 lncRNAs were correlated with AR pathophysiology. | (57) |

(Continued)
revealed that lncRNAs might be an important class of therapeutic targets in renal injuries after transplantation.

### 2.1.5 Stem Cell

Lyu et al. conducted an integrated microarray analysis of lncRNAs and mRNAs in brain tissue of rats prone to traumatic brain injury (TBI). Induced pluripotent stem cells (iPSCs) -derived A2B5+ (A2B5+iPSC) cells were transplanted into the injured site of rat brain. They found 83 lncRNAs and 360 mRNAs between A2B5+iPSC and TBI groups differently expressed. A2B5+iPSC transplantation could effectively ameliorate neurological dysfunction in the brain tissue of rats in the TBI group. The mechanism of improvement is mainly related to the alteration of lncRNA and mRNA expression,
specially ENSRNOT00000052577 lncRNA and its target mRNA, kinesin family member 2C (Kif2C). This study showed that ENSRNOT00000052577 and Kif2C were downregulated in the A2B5\textsuperscript{*}iPSC group versus the TBI group (fold change 2.07 and 2.08, respectively) (48). Another study using a murine hematopoietic stem cell transplantation (HSCT) model discovered differentially expressed lncRNAs in hepatocytes using a microarray approach. The findings displayed that 1911 and 2918 lncRNAs were downregulated and upregulated, respectively, and may be involved in hepatocyte damage after HSCT. Among these dysregulated lncRNAs, there were 148/183 (down-/upregulated lncRNAs) bidirectional, 795/1473 intergenic, 209/421 intronic antisense, 304/327 natural antisense, 380/327 exon sense-overlapping, and 75/187 intronic sense-overlapping. Additionally, these lncRNAs were correlated with a dysregulation in the expression of various adjacent coding genes, such as upregulation of the T cell receptor (TCR) and with a dysregulation in the expression of various adjacent coding genes, such as upregulation of the T cell receptor (TCR) and downregulation of the vascular endothelial growth factor (VEGF) pathways (49).

2.1.6 Cornea
The first study about the function of lncRNAs in corneal transplantation was explored by Wen et al. in the rat models of corneal allograft and autograft. They identified 162 differentially expressed lncRNAs in the allograft compared to the autograft group, among which 142 were upregulated, and 20 were downregulated, and it seems these dysregulated lncRNAs involved in the occurrence of allograft rejection 14 days after corneal transplantation (50).

2.2 Human Studies
2.2.1 Kidney
Several lncRNAs regulate gene expression and phenotype without altering the underlying DNA sequence only via interfering with protein activity, stability, and localization. As an important prerequisite to figure out signaling pathways in acute renal rejection, several studies have investigated the interaction between transcription factors (TFs), miRNAs, and lncRNAs by an integrated bioinformatic analysis of related datasets as the first step toward better comprehending the regulation of gene expression in acute rejection (AR) following renal transplantation (57).

The function of lncRNAs in epigenetic and gene regulation is well evidenced (66). Therefore, the finding of these studies that thousands of lncRNAs are differentially expressed in AR and healthy samples is not surprising.

Multiple lncRNAs have been shown to be dysregulated in the urine of renal transplant patients with acute T cell-mediated rejection (aTCMR). Lorenzen et al. found that three intergenic lncRNAs, RP11-354P17.15-001 (L-328), RP11-395P13.3-001 (L-327), and LNC-MYH13-3:1 (L-321), were most strongly changed in the urine of patients with acute rejection. L-328 and L-327 have upregulated in patients who experienced acute rejection compared with stable subjects. Moreover, only the expression level of L-328 decreased in patients with successful anti-rejection therapy and was also associated with a higher reduction in glomerular filtration rate (GFR) one-year after transplantation. Surprisingly, 83.61% of patients experienced subclinical rejection (i.e., no change in creatinine level) that were identifiable by L-328 expression level. Thus, in addition to aTCMR, the subclinical rejection which would have been missed by routine serum creatinine measurements could also be evaluated by L-328 level (51). In line with this study, Qiu and colleagues have also proposed that lncRNA-ATB, lncRNA activated by transforming growth factor-beta 1 (TGF-β1), could be utilized as a potential diagnostic biomarker to identify aTCMR and predict loss of renal function. This lncRNA could function as a competing endogenous RNAs (ceRNA) by competitively binding to miR-200c and thus inversely correlated with the expression level of miR-200c in renal biopsies of aTCMR patients. Moreover, treatment of human renal proximal tubule cells HK-2 with TGF-β revealed that miR-200c downregulated, while lncRNA-ATB was strongly upregulated. Meanwhile, overexpression of lncRNA-ATB induces cyclosporin A (CsA)-dependent renal cell apoptosis as well as influences on renal cell phenotype (12).

Additionally, multiple transcriptomic studies have reported a large number of dysregulated lncRNAs in whole blood (AB209021 and AF264622) (10), peripheral blood mononuclear cells (AC007114.2, AL122035.2, AL591848.3, IQCH-AS1, KLF3-AS1, PVT1, SLC25A25-AS1, and TMEM161B-AS1) (56), and tissue biopsies (ITGB2-AS1, CARD8-AS1, MIR155HG, MIR3142HG, RP5-1171I10.5, RP11-1399P15.1, RP11-522B15.3, lnc-EPHA1-1, XIST, ATP1A1-AS1, LINC00645, CTD-3080P12.3, EMX2OS, lncRNA ENST000000628900, RP11-309P22.1, AF113674, Uc010ftb, Uc001fyy, Uc003wbj, and AK129917) (11,14,16,53,58,60) of renal allograft rejected patients compared to stable graft function recipients. Moreover, an acute rejection risk score model with some of these lncRNAs exhibited good diagnostic performance; for example, AB209021 and AF264622 in both pediatric and adult renal transplant patients could serve as a novel biomarker for acute rejection diagnosis (10). Zou et al. validated a risk score with a set of three related lncRNAs including ITGB2-AS1, MIR155HG, and CARD8-AS1 for predicting graft loss in transplant patients. Kidney transplant patients with higher risk scores expressed higher levels of these three lncRNAs in their biopsies (14). Also, a sensitive and specific risk score model was established using CTD-3080P12.3, ATP1A1-AS1, LINC00645, and EMX2OS that could predict allograft survival 1-, 2-, and 3-year post-transplantation (53). In a recent study, Nagarajah et al. showed that an intronic antisense lncRNA, called MGAT3-AS1, which was obtained from PBMC, was increased in patients with immediate graft function (IGF) and could thus provide information about the short-term outcome after renal transplantation. In contrast to IGF patients, the expression level of MGAT3-AS1 was downregulated in renal transplants with delayed graft function (DGF) (34). Furthermore, a lower MGAT3-AS1/β-actin ratio has been shown to increase the risk of cytomegalovirus and BK polyomavirus viremia in the first month after transplantation. Patients who had received induction therapy either with
rituximab or thymoglobulin and had a lower MGAT3-AS1/β-actin depicted an elevated risk for viremia (55). A recent study showed that demographic patient parameters such as gender can affect expression levels of some lncRNAs like FAS-AS1 (52).

2.2.2 Lung

XIST lncRNA was highly expressed in the bronchoalveolar lavage fluid (BALF) and BAL cells of the primary graft dysfunction (PGD) cohort. XIST acts as a regulatory sponge for miR-21 and thereby increases levels of neutrophil-infiltrating factor, such as IL-12A, a target gene for miR-21. Ultimately, by NET formation, neutrophils accelerate PGD occurrence after lung transplantation. Furthermore, reduced expression levels of miR-21 in BAL cells of PGD patients than those of non-PGD ones confirmed the ceRNA function of XIST. Additionally, the expression level of miR-21 was also negatively correlated with the grade of PGD. Moreover, the protein levels of pro-inflammatory mediators, including IL-6, IL-8, CCL-2, and CXCL10, were elevated in the PGD patients compared to non-PGD. Whilst macrophages were the main leukocyte population in the BALF of non-PGD patients, the major leukocyte population in BALF of the PGD patients were PMNs (43).

2.2.3 Hematopoietic Stem Cell Transplantation (HSCT)

It has been discovered that polymorphism in ANRIL lncRNA is associated with the overall survival in adult patients with hematologic malignancies after HSCT. rs2151280 in ANRIL was related to the poorer overall survival in these patients. Conversely, none of the four investigated SNPs rs564398, rs1063192, rs2151280, and rs2157719 were associated with the overall survival in adult patients with hematologic malignancies after HSCT. (62). It has been discovered that polymorphism in ANRIL lncRNA is associated with the overall survival in adult patients with hematologic malignancies after HSCT. rs2151280 in ANRIL was related to the poorer overall survival in these patients. Conversely, none of the four investigated SNPs rs564398, rs1063192, rs2151280, and rs2157719 were associated with the overall survival in adult patients with hematologic malignancies after HSCT. (62).

The underlying mechanism could be attributed to ANRIL-dependent transcription suppression on the ARF-INK4 gene. Furthermore, rs2151280 might serve as a potential prognostic biomarker for overall survival in patients suffering from hematologic malignancies after HSCT. (62).

3 THE POTENTIAL ROLES OF LNCRNAS AS A BIOMARKER

Many studies have widely explored the noninvasive biomarkers for allograft rejection. For example, urinary/circulating blood concentrations of soluble adhesion molecules, chemokines, cytokines, the lymphocyte expression of granzyme B, perforin, and Fas ligand (FasL), as well as the urokinase plasminogen activator receptor (uPAR) have been assessed previously as the potential biomarkers for the allograft rejection (67). However, the clinical application of these biomarkers has not been successfully proven yet. Therefore, finding the potential biomarkers with high specificity and sensitivity, as it has been shown for some lncRNAs, can be a beneficial tool in the transplantation field. Several lncRNAs with appropriate sensitivity and specificity for detecting transplant rejection are shown in Table 3.

4 FUTURE LANDSCAPE FOR THE CLINICAL USE OF LNCRNAS IN THE TRANSPLANTATION

Among various diagnostics parameters, tissue biopsy is considered a gold standard for diagnosing allograft rejection. Nevertheless, it is highly invasive and a risky procedure. Moreover, sampling errors and interobserver variations can further complicate the diagnosis of graft rejection. Therefore,
identifying accurate, sensitive, and noninvasive biomarkers is essentially needed to diagnose subclinical transplant rejection. Ideally, such biomarkers could also become the cornerstone of personalized therapy. They would allow clinicians to decrease immunosuppression in patients with a low rejection risk and/or high risk of neoplastic complications or infection and also adapt the immunosuppressive protocol in high rejection risk patients. Over the past few years, many of the ncRNAs have been demonstrated to play a major function in determining the allograft status and thus have shown promise as potential therapeutic targets. Among ncRNA families, the subfamily of lncRNAs have recently emerged as the lead targets in the area of transplant research, and widespread efforts have been made towards the clinical application of these RNA-based diagnostics for monitoring the allograft loss after transplantation. It seems that these molecules can overcome the need for diagnostic biopsy and identify patients with a poor prognostic outcome of the allograft. As mentioned previously, several lncRNAs in different types of organ transplantation have been studied so far, but the transition from discovery to validation status is a major challenge, and large multi-center prospective clinical trials are now significantly required for accelerating the implementation of lncRNAs into the clinic. However, according to the recent studies (10,14,53), an interesting strategy could be using a set of lncRNAs to design a composite lncRNA-based risk score model to predict the risk of graft failure and the occurrence of complications after transplantation. These composite predictive models probably guide clinicians in choosing or adjusting the immunosuppressive drugs after transplantation.

Nonetheless, it is necessary to note that the findings described in recent studies are merely a starting point for the comprehension of functions that lncRNAs may play in transplant rejection episodes. In this context, it is worth noting that only the function of a minority of lncRNAs is been shown presently and further studies are required to characterize the exact role of lncRNAs for clinical use in transplantation.

**AUTHOR CONTRIBUTIONS**

**SS:** The design and conception of the study and revising the manuscript critically for important intellectual content. **AS:** The design and conception of the study and revising the manuscript critically for important intellectual content. **AA:** The design and conception of the study and revising the manuscript critically for important intellectual content. **YM:** The design and conception of the study and revising the manuscript critically for important intellectual content. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Hart A, Lentine KL, Smith JM, Miller JM, Skeans MA, Prentice M, et al. OPTN/SRTR 2019 Annual Data Report: Kidney. *Am J Transplant* (2021) 21:21–137. doi: 10.1111/ajt.16502
2. Valapour M, Lehr CJ, Skeans MA, Smith JM, Miller E, Goff R, et al. OPTN/SRTR 2019 Annual Data Report: Lung. *Am J Transplant* (2021) 21:441–520. doi: 10.1111/ajt.16495
3. Colvin M, Smith JM, Ahn Y, Skeans MA, Messick E, Goff R, et al. OPTN/SRTR 2019 Annual Data Report: Heart. *Am J Transplant* (2021) 21:356–440. doi: 10.1111/ajt.16492
4. Kwong AJ, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, et al. OPTN/SRTR 2019 Annual Data Report: Liver. *Am J Transplant* (2021) 21:208–315. doi: 10.1111/ajt.16494
5. Horslen SP, Smith JM, Ahn Y, Skeans MA, Cafarella M, Noreen SM, et al. OPTN/SRTR 2019 Annual Data Report: Intestine. *Am J Transplant* (2021) 21:316–55. doi: 10.1111/ajt.16498
6. Kandaswamy R, Stock PG, Miller J, Skeans MA, White J, Wainright J, et al. OPTN/SRTR 2019 Annual Data Report: Pancreas. *Am J Transplant* (2021) 21:138–207. doi: 10.1111/ajt.16496
7. Hickman PE, Potter JM, Pesce AJ. Clinical Chemistry and Post-Liver-Transplant Monitoring. *Clin Chem* (1997) 43:1546–54. doi: 10.1093/clinchem/43.8.1546
8. Verhoeven J, Boer K, Van Schak RHNL, Manintveld OC, Huibers MMH, Baan CC, et al. Liquid Biopsies to Monitor Solid Organ Transplant Function: A Review of New Biomarkers. *Ther Drug Monit* (2018) 40:515–25. doi: 10.1097/FTD.0000000000000549
9. Ryan NP, Ian BN, Jennifer HF. The Use of Genomics and Proteomics for the Recognition of Transplantation Rejection of Solid Organs. *Recent Patents DNA Gene Sequences* (Discontinued) (2009) 3:1–6. doi: 10.2174/187221509787236165
10. Ge YZ, Xu T, Cao WJ, Wu R, Yao WT, Zhou CC, et al. A Molecular Signature of Two Long Non-Coding RNAs in Peripheral Blood Predicts Acute Renal Allograft Rejection. *Cell Physiol Biochem* (2017) 44:1213–23. doi: 10.1159/000485451
11. Gu G, Huang Y, Wu C, Guo Z, Ma Y, Xia Q, et al. Differential Expression of Long Noncoding RNAs During Cardiac Allograft Rejection. *Transplantation* (2017) 101:83–91. doi: 10.1097/TP.0000000000001463
12. Qiu J, Chen Y, Huang G, Zhang Z, Chen L, Na N. Transforming Growth Factor-β Activated Long Non-Coding RNA ATB Plays an Important Role in Acute Rejection of Renal Allografts and may Impacts the Postoperative Pharmacological Immunosuppression Therapy. *Nephril* (Carlton) (2017) 22:796–803. doi: 10.1111/dep.12851
13. Arbisi-Roca A, Padró-Miquel A, Vidal-Alabró A, Hueso M, Fontova P, Bestard O, et al. ANRIL as a Genetic Marker for Cardiovascular Events in Renal Transplant Patients - An Observational Follow-Up Cohort Study. *Transpl Int* (2018) 31:1018–27. doi: 10.1111/tri.13276
14. Zou Y, Zhang W, Zhou HH, Liu R. Analysis of Long Noncoding RNAs for Acute Rejection and Graft Outcome in Kidney Transplant Biopsies. *Biomark Med* (2019) 13:185–95. doi: 10.2217/bmm-2018-0272
15. Groeneweg KE, Duits J, Florijn BW, Van Kooten C, De Fijter JW, Van Zonneveld AJ, et al. Circulating Long Noncoding RNA LNC-EPHA6 Associates With Acute Rejection After Kidney Transplantation. *Int J Mol Sci* (2020) 21. doi: 10.3390/ijms21165616
16. Xu J, Hu J, Xu H, Zhou H, Liu Z, Zhou Y, et al. Long Non-Coding RNA Expression Profiling in Biopsy to Identify Renal Allograft at Risk of Chronic Damage and Future Graft Loss. *Appl Biochem Biotechnol* (2020) 190:660–73. doi: 10.1007/s12010-019-03082-2
17. The EPC, Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, et al. An Integrated Encyclopedia of DNA Elements in the Human Genome. *Nature* (2012) 489:57. doi: 10.1038/nature11247
18. Hombach S, Kretz M. Non-Coding RNAs: Classification, Biology and Functioning. *Adv Exp Med Biol* (2016) 937:3–17. doi: 10.1007/978-3-319-42059-2_1
19. Wei JW, Huang K, Yang C, Kang CS. Non-Coding RNAs as Regulators in Epigenetics (Review). *Oncof Rep* (2017) 37:3–9. doi: 10.3892/or.2016.5236
20. Boivin V, Faucher-Giguère I, Scott M, Abou-Elela S. The Cellular Landscape of Mid-Sized Noncoding RNA. WIREs RNA (2019) 10:e1530. doi: 10.1002/ wrna.1530.

21. Ponting CP, Oliver PL, Reik W. Evolution and Functions of Long Noncoding RNAs. Cell (2009) 136:629–41. doi: 10.1016/j.cell.2009.02.006.

22. Jarroux J, Morilllon A, Pinskaya M. History, Discovery, and Classification of IncRNAs. Adv Exp Med Biol (2017) 1008:1–46. doi: 10.1007/978-91-10-5203-3_1.

23. Wang KC, Chang HY. Molecular Mechanisms of Long Noncoding RNAs. Mol Cell (2011) 43:904–14. doi: 10.1016/j.molcel.2011.08.018.

24. Khandelwal A, Bacolla A, Vasquez KM, Jain A. Long Non-Coding RNA: A New Paradigm for Lung Cancer. Mol Carcinog (2015) 54:1235–51. doi: 10.1002/mc.22523.

25. Fung Y, Fullwood MJ. Roles, Functions, and Mechanisms of Long Non-Coding RNAs in Cancer. Genomics Proteomics Bioinf (2016) 14:42–54. doi: 10.1016/j.gpb.2015.09.006.

26. Attianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of Long Non Coding RNAs. Annu Rev Immunol (2017) 35:177–98. doi: 10.1146/ annurev-immunol-041015-055459.

27. Uszczynska-Ratajczak B, Lagarde J, Frankish A, Guigo R, Johnson R. Towards a Complete Map of the Human Long Non-Coding RNA Transcriptome. Nat Rev Genet (2018) 19:535–48. doi: 10.1038/s41576-018-0017-y.

28. Stachurska A, Zorro MM, van der Sijde MR, Withoff S. Small and Long Noncoding RNAs. IUBMB Life (2018) 46:D308–14. doi: 10.1002/iub.2853.

29. Ma L, Bajic VB, Zhang Z. On the Classification of Long Non-Coding RNAs. RNA Biol (2013) 10:925–33. doi: 10.4161/rna.24604.

30. Frankish A, Diekhans M, Ferreira A-M, Johnson R, Jungreis I, Loveland J, et al. GENCODE Reference Annotation for the Human and Mouse Genomes. Nucleic Acids Res (2018) 47:D766–73. doi: 10.1093/nar/gky955.

31. Fang S, Zhang L, Guo J, Niu Y, Wu Y, Li H, et al. NONCODEV5: A Database of Non-Coding RNA in Human Genomes. IUBMB Life (2019) 71:634–7. doi: 10.1002/iub.1479.

32. Mathy NW, Chen X-M. Long non-Coding RNAs (lncRNAs) and Their Transcriptional Control of Inflammatory Responses. J Biol Chem (2017) 292:12375–82. doi: 10.1074/jbc.R116.760884.

33. Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z, et al. Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. Int J Mol Sci (2019) 20:5573. doi: 10.3390/ijms20225573.

34. Leung A, Natarajan R. Long Noncoding RNAs in Diabetes and Diabetic Complications. Antioxidants Redox Signaling (2018) 29:1064–73. doi: 10.1089/ars.2017.7315.

35. Xiong M-X, Xu H-S. Involvement of Long non-Coding RNAs in the Pathogenesis of Rheumatoid Arthritis. Chin Med J (2020) 133:941–50. doi: 10.1097/CM9.0000000000000755.

36. Mathy NW, Chen X-M. Long non-Coding RNAs (lncRNAs) and Their Transcriptional Control of Inflammatory Responses. J Biol Chem (2017) 292:12375–82. doi: 10.1074/jbc.R116.760884.

37. Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z, et al. Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. Int J Mol Sci (2019) 20:5573. doi: 10.3390/ijms20225573.

38. Schmitz SU, Grote P, Herrmann BG. Mechanisms of Long Noncoding RNA Function in Development and Disease. Cell Mol Life Sci (2016) 73:2491–509. doi: 10.1007/s00018-016-2174-5.

39. Zhang M, Zheng Y, Sun Y, Li S, Chen L, Jin X, et al. Knockdown of NEAT1 Induces Tolerogenic Phenotype in Dendritic Cells by Inhibiting Activation of NLRP3 Inflammasome. Theranostics (2019) 9:3425–42. doi: 10.7150/ thno.33178.

40. Wu J, Zhang H, Zheng Y, Jin X, Liu M, Li S, et al. The Long Noncoding RNA MALAT1 Induces Tolerogenic Dendritic Cells and Regulatory T Cells via MiR155/Dendritic Cell-Specific Intercellular Adhesion Molecule-3 Grabbing Nonintegrin/IL10 Axis. Front Immunol (2019) 9:1847. doi: 10.3389/ fi.imm.2018.01847.

41. Chen S, Fang H, Li J, Shi J, Zhang J, Wen P, et al. Microarray Analysis For Expression Profiles of IncRNAs and circRNAs in Rat Liver After Brain-Dead Donor Liver Transplantation. BioMed Res Int (2019) 2019:5604843. doi: 10.1155/2019/5604843.
60. Cheng Q, Wang L. LncRNA XIST Serves as a ceRNA to Regulate the Expression of ASF1A, BRWD1M, and PFKFB2 in Kidney Transplant Acute Kidney Injury via Sponging hsa-miR-212-3p and hsa-miR-122-5p. Cell Cycle (2020) 19:290–9. doi: 10.1080/15384101.2019.1707454

61. Groeneweg KE, Au YW, Duij J, Florijn BW, Van Kooten C, De Fijter JW, et al. Diabetic Nephropathy Alters Circulating Long Noncoding RNA Levels That Normalize Following Simultaneous Pancreas-Kidney Transplantation. Am J Transplant (2020) 20:3451–61. doi: 10.1111/ajt.15961

62. Li J, Seligson N, Zhang X, Johnson J, Vangundy Z, Wang D, et al. Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Anticancer Res (2020) 40:5707–13. doi: 10.21873/ anticancer.14585

63. Volders PJ, Anckaert J, Verheggen K, Nuytens J, Martens L, Mestdagh P, et al. LNCipedia 5: Towards a Reference Set of Human Long Non-Coding RNAs. Nucleic Acids Res (2019) 47:D135–d139. doi: 10.1093/nar/gky1031

64. Wu J, Li S, Zheng Y, Zhang M, Zhang H, Sun Y, et al. Silencing of lncRNA NEAT1 Induces Tolerogenic Dendritic Cells and Immune Tolerance in Heart Transplantation. J Immunol (2017) 198:82.27. doi: 10.3389/fimmu.2018.01847

65. Zou XF, Song B, Duan JH, Hu ZD, Cui ZL, Gu C. Prolonged Ischemia Elicits Acute Allograft Rejection Involved in CXCR3 Activation in Rat Kidney Transplants. Transpl Immunol (2015) 33:103–9. doi: 10.1016/j.trim.2015.08.001

66. Wang C, Wang L, Ding Y, Lu X, Zhang G, Yang J, et al. LncRNA Structural Characteristics in Epigenetic Regulation. Int J Mol Sci (2017) 18. doi: 10.3390/ijms18122659

67. Gwinner W. Renal Transplant Rejection Markers. World J Urol (2007) 25:445–55. doi: 10.1007/s00345-007-0211-6

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily reflect those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Salehi, Afzali, Shadi, Amirzargar and Mansoori. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.